Vancouver, BC & Tokyo & Waltham, Mass. – SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; “Modalis”), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting …
Vancouver, British Columbia and Columbus, Ohio, May 6, 2025 — SOLVE FSHD, a venture philanthropy organization committed to accelerating therapies for facioscapulohumeral muscular dystrophy (FSHD), today announced a $3 million investment in Armatus Bio, a biotechnology company developing next-generation vectorized RNAi therapeutics for neuromuscular diseases. The investment will support ARM-201, Armatus Bio’s AAV-delivered microRNA therapy …
Vancouver, BC, March 25, 2025 – SOLVE FSHD, a venture philanthropic organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), is pleased to announce a strategic collaboration with Transcripta Bio, a cutting-edge AI-driven drug discovery company. This collaboration will focus on leveraging Transcripta Bio’s advanced drug screening platform to identify and develop promising therapeutic candidates …
Cambridge, Mass., May 12, 2025 – Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, today announced it has been named a Finalist Team in XPRIZE Healthspan FSHD Bonus Prize, earning a $250,000 Milestone Award for its work addressing facioscapulohumeral muscular dystrophy (FSHD), one of the most prevalent forms of muscular dystrophy globally. Epicrispr was one of eight global …
Columbus, Ohio, May 12, 2025 – Armatus Bio, a late-preclinical stage biotech innovator developing vectorized RNAi medicines in neuromuscular disorders, today announced its recognition as one of eight finalists in the XPRIZE Healthspan FSHD Bonus Prize, led by XPRIZE, the world’s leader in designing and operating large-scale incentive competitions to solve humanity’s grand challenges. SOLVE …
SOLVE FSHD Provides Funding to n-Lorem for a Collaboration to Expand Understanding of FSHD2, a Rare Form of Muscular Dystrophy SOLVE FSHD contributes more than $1 million to n-Lorem to support research efforts to inform a therapeutic strategy for FSHD2 nano-rare patients SAN DIEGO, Calif., Sept. 9, 2022, n-Lorem, a nonprofit foundation, today announced that Solve …